Given the emerging insights into the involvement of the COX/LOX axis in cancer pathogenesis and the success of several sulfonamide derivatives as anticancer therapeutics, our research aims to delve deeper into the potential anticancer properties of the sulfonamide antibiotic sulfadiazine. This evidence concerns the gene LOX and cancer.